|
Recent Developments in Drug Therapy for Aplastic Anemia
|
Sep 2014
|
Ann Pharmacother
|
aplastic anemia
|
|
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Sep 2014
|
Ann Oncol
|
myelodysplastic syndromes (MDS)
|
|
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
|
Oct 2015
|
Ann Oncol
|
myelodysplastic syndromes (MDS)
|
|
Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum
|
Mar 2014
|
Ann N Y Acad Sci
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes in the United States: an update for clinicians
|
Apr 2014
|
Ann Med.
|
myelodysplastic syndromes (MDS)
|
|
A novel marker for screening paroxysmal nocturnal hemoglobinuria using routine complete blood count and cell population data
|
Jan 2015
|
Ann Lab Med
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
|
Apr 2012
|
Ann Hematol.
|
aplastic anemia
|
|
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
|
Sep 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II
|
Nov 2016
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide
|
May 2014
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
